サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468495

経口タンパク質・ペプチド市場：薬剤タイプ、用途、地域別、2024～2032年

Oral Proteins and Peptides Market by Drug Type (Linaclotide, Plecanatide, Calcitonin, Insulin, Octreotide), Application (Gastric and Digestive Disorders, Bone Diseases, Diabetes, Hormonal Disorders), and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 136 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.91円
経口タンパク質・ペプチド市場：薬剤タイプ、用途、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 136 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の経口タンパク質・ペプチド市場規模は2023年に17億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに33億米ドルに達し、2024～2032年の間に7.51%の成長率（CAGR）を示すと予測しています。慢性疾患の蔓延拡大、高齢者人口の増加、消費者の経口薬嗜好の高まりなどが、市場を牽引する主要要因となっています。

タンパク質とペプチドは人体の天然成分であり、多くの生物学的プロセスで重要な役割を果たしています。構造が複雑で胃や小腸で消化されやすいため、通常は注射で投与されます。しかし、経口タンパク質やペプチドは、ホルモン、胃、代謝障害を治療するために、経口経路から摂取することができます。このような課題を克服するために、分子を消化から守り、腸壁から血流に吸収されるような特殊な製剤が設計されています。これらの製剤には、腸溶性コーティング、ナノ粒子、その他のデリバリー技術が含まれます。経口タンパク質・ペプチドは、糖尿病、がん、自己免疫疾患など数多くの慢性疾患の治療に広く利用されています。

経口タンパク質・ペプチド市場の動向：

がん、糖尿病、心血管障害（CVDs）、後天性免疫不全症候群（AIDs）などの慢性疾患に罹患する患者の増加、高齢者人口の増加が経口タンパク質とペプチド市場の成長を促進する主要要因です。このほか、嗜好の変化や、大衆の間で効果的な経口薬や技術に対する需要が高まっていることも、市場の成長に寄与しています。さらに、消費者の健康意識の高まりと、経口タンパク質・ペプチドサプリメントの摂取に関連する数多くの利点に対する意識の高まりが、市場に明るい展望を生み出しています。これに加えて、三次元（3D）プリンティング、ナノ技術、遺伝子工学などの革新的な技術の進歩により、メーカーはより高度でコスト効率の高い製品バリエーションを製造できるようになり、これも重要な成長促進要因として作用しています。これと同時に、製薬企業間の広範な協力体制、医療インフラの大幅な進歩、研究開発（R&D）活動の活発化も、市場に有益な成長機会をもたらしています。さらに、消費者の可処分所得の増加、タンパク質が豊富な食生活の普及、プロテインパウダー、バー、シェイクの需要の急増、製品への容易なアクセスを提供するオンラインプラットフォームの普及が、市場の拡大を後押ししています。

本レポートで扱う主要質問

  • 世界の経口タンパク質・ペプチド市場はこれまでどのように推移してきたか？
  • 世界の経口タンパク質・ペプチド市場における促進要因、抑制要因、機会は何か？
  • それぞれの促進要因、抑制要因、機会が世界の経口タンパク質・ペプチド市場に与える影響は？
  • 主要な地域市場は？
  • 最も魅力的な経口タンパク質・ペプチド市場を代表する国は？
  • 薬剤タイプ別の市場内訳は？
  • 経口タンパク質・ペプチド市場で最も魅力的な薬剤タイプは？
  • 用途別の市場内訳は？
  • 経口タンパク質・ペプチド市場で最も魅力的な用途はどれですか？
  • 世界の経口タンパク質・ペプチド市場の競合構造は？
  • 世界の経口タンパク質・ペプチド市場の主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界の経口タンパク質・ペプチド市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤タイプ別

  • リナクロチド
  • プレカナチド
  • カルシトニン
  • インスリン
  • オクトレオチド

第7章 市場内訳：用途別

  • 胃・消化器疾患
  • 骨疾患
  • 糖尿病
  • ホルモン疾患

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amryt Pharma Plc
    • AstraZeneca PLC
    • Biocon Limited
    • Novo Nordisk A/S
    • Oramed Ltd
    • Proxima Concepts Limited
図表

List of Figures

  • Figure 1: Global: Oral Proteins and Peptides Market: Major Drivers and Challenges
  • Figure 2: Global: Oral Proteins and Peptides Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Oral Proteins and Peptides Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Oral Proteins and Peptides Market: Breakup by Drug Type (in %), 2023
  • Figure 5: Global: Oral Proteins and Peptides Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Oral Proteins and Peptides Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Oral Proteins and Peptides (Linaclotide) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Oral Proteins and Peptides (Linaclotide) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Oral Proteins and Peptides (Plecanatide) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Oral Proteins and Peptides (Plecanatide) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Oral Proteins and Peptides (Calcitonin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Oral Proteins and Peptides (Calcitonin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Oral Proteins and Peptides (Insulin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Oral Proteins and Peptides (Insulin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Oral Proteins and Peptides (Octreotide) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Oral Proteins and Peptides (Octreotide) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Oral Proteins and Peptides (Gastric and Digestive Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Oral Proteins and Peptides (Gastric and Digestive Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Oral Proteins and Peptides (Bone Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Oral Proteins and Peptides (Bone Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Oral Proteins and Peptides (Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Oral Proteins and Peptides (Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Oral Proteins and Peptides (Hormonal Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Oral Proteins and Peptides (Hormonal Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: North America: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: North America: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: United States: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: United States: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Canada: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Canada: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Asia-Pacific: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Asia-Pacific: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: China: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: China: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Japan: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Japan: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: India: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: India: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: South Korea: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: South Korea: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Australia: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Australia: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Indonesia: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Indonesia: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Others: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Others: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Europe: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Europe: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Germany: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Germany: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: France: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: France: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: United Kingdom: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: United Kingdom: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Italy: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Italy: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Spain: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Spain: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Russia: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Russia: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Latin America: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Latin America: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Brazil: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Brazil: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Mexico: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Mexico: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Others: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Others: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Middle East and Africa: Oral Proteins and Peptides Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Middle East and Africa: Oral Proteins and Peptides Market: Breakup by Country (in %), 2023
  • Figure 73: Middle East and Africa: Oral Proteins and Peptides Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Global: Oral Proteins and Peptides Industry: Drivers, Restraints, and Opportunities
  • Figure 75: Global: Oral Proteins and Peptides Industry: Value Chain Analysis
  • Figure 76: Global: Oral Proteins and Peptides Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Oral Proteins and Peptides Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Oral Proteins and Peptides Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Oral Proteins and Peptides Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Oral Proteins and Peptides Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Oral Proteins and Peptides Market: Competitive Structure
  • Table 6: Global: Oral Proteins and Peptides Market: Key Players
目次
Product Code: SR112024A7530

The global oral proteins and peptides market size reached US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7.51% during 2024-2032. The expanding prevalence of chronic diseases, the rising geriatric population, and the increasing preference for oral drugs among consumers represent some of the key factors driving the market.

Proteins and peptides are natural components of the human body and play essential roles in many biological processes. Due to their complex structure and susceptibility to digestion in the stomach and small intestine, they are usually administered through injections. However, oral proteins and peptides can be taken via the oral path to treat hormonal, gastric, and metabolic disorders. They are designed to overcome these challenges by using specialized formulations that protect the molecules from digestion and allow them to be absorbed through the intestinal wall into the bloodstream. These formulations include enteric coatings, nanoparticles, and other delivery technologies. Oral proteins and peptides are extensively utilized to treat numerous chronic diseases, such as diabetes, cancer, and autoimmune disorders.

Oral Proteins and Peptides Market Trends:

The increasing volume of patients suffering from chronic diseases, such as cancer, diabetes, cardiovascular disorders (CVDs), and acquired immunodeficiency syndrome (AIDs), and the expanding geriatric population represent the key factors driving the oral proteins and peptides market growth. Besides this, shifting preferences and the rising demand for effective oral drugs and technology among the masses are contributing to the market growth. Moreover, the escalating consumer health consciousness and the growing awareness of the numerous benefits associated with the consumption of oral protein and peptide supplements are creating a positive outlook for the market. In addition to this, innovative technological advancements, such as three-dimensional (3D) printing, nanotechnology, and genetic engineering, have enabled manufacturers to produce more advanced and cost-effective product variants, which is acting as another significant growth-inducing factor. Concurrent with this, the extensive collaborative efforts between pharmaceutical companies, significant advancements in the healthcare infrastructure, and rising research and development (R&D) activities are presenting remunerative growth opportunities for the market. Furthermore, the inflating disposable income of consumers, the widespread adoption of protein-rich diets, the surging demand for protein powder, bars, and shakes, and the increasing proliferation of online platforms providing easy product access are aiding in market expansion.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global oral proteins and peptides market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on drug type and application.

Drug Type Insights:

Linaclotide

Plecanatide

Calcitonin

Insulin

Octreotide

The report has provided a detailed breakup and analysis of the oral proteins and peptides market based on the drug type. This includes linaclotide, plecanatide, calcitonin, insulin, and octreotide. According to the report, insulin represented the largest segment.

Application Insights:

Gastric and Digestive Disorders

Bone Diseases

Diabetes

Hormonal Disorders

A detailed breakup and analysis of the oral proteins and peptides market based on the application has also been provided in the report. This includes gastric and digestive disorders, bone diseases, diabetes, and hormonal disorders. According to the report, diabetes accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for oral proteins and peptides. Some of the factors driving the North America oral proteins and peptides market included the increasing prevalence of chronic diseases, the shifting consumer preference for oral drugs, and innovative product advancements.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global oral proteins and peptides market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amryt Pharma Plc, AstraZeneca PLC, Biocon Limited, Novo Nordisk A/S, Oramed Ltd, Proxima Concepts Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global oral proteins and peptides market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global oral proteins and peptides market?
  • What is the impact of each driver, restraint, and opportunity on the global oral proteins and peptides market?
  • What are the key regional markets?
  • Which countries represent the most attractive oral proteins and peptides market?
  • What is the breakup of the market based on the drug type?
  • Which is the most attractive drug type in the oral proteins and peptides market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the oral proteins and peptides market?
  • What is the competitive structure of the global oral proteins and peptides market?
  • Who are the key players/companies in the global oral proteins and peptides market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oral Proteins and Peptides Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Linaclotide
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Plecanatide
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Calcitonin
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Insulin
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Octreotide
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Gastric and Digestive Disorders
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Bone Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Diabetes
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Hormonal Disorders
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 Drivers, Restraints, and Opportunities

  • 9.1 Overview
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Opportunities

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Amryt Pharma Plc
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
    • 13.3.2 AstraZeneca PLC
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Biocon Limited
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Novo Nordisk A/S
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Oramed Ltd
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 Proxima Concepts Limited
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.